This company listing is no longer active
Tsubota Laboratory Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Tsubota Laboratory has been growing earnings at an average annual rate of 2.1%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 0.02% per year. Tsubota Laboratory's return on equity is 1.3%, and it has net margins of 3.2%.
Anahtar bilgiler
2.1%
Kazanç büyüme oranı
-0.02%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | 0.02% |
Özkaynak getirisi | 1.3% |
Net Marj | 3.2% |
Sonraki Kazanç Güncellemesi | 10 Nov 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Tsubota Laboratory nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 23 | 750 | 24 | 446 | 126 |
31 Mar 23 | 954 | 90 | 394 | 126 |
31 Dec 22 | 972 | 139 | 368 | 116 |
31 Mar 22 | 640 | 153 | 276 | 116 |
31 Mar 21 | 687 | 201 | 356 | 0 |
31 Mar 20 | 441 | 3 | 262 | 0 |
Kaliteli Kazançlar: TSUB.F has high quality earnings.
Büyüyen Kar Marjı: TSUB.F's current net profit margins (3.2%) are lower than last year (19.8%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: TSUB.F's earnings have grown by 2.1% per year over the past 5 years.
Büyüme Hızlandırma: TSUB.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: TSUB.F had negative earnings growth (-83.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-17.3%).
Özkaynak Getirisi
Yüksek ROE: TSUB.F's Return on Equity (1.3%) is considered low.